Jinwu Financial News | BOC International said that documents have been issued in many places to support the high-quality development of the biomedical industry. Beijing emphasized separate payments for innovative drugs, while Guangzhou and Zhuhai provided strong financial support. The biotech sector rose 3.9% this week, ranking first among all pharmaceutical sub-sectors. The bank is optimistic about the long-term development prospects of the innovative drug industry, and continues to promote innovative pharmaceutical companies with differentiated products, an international layout, and rich and important data readout/important regulatory approval catalysts during the year, including Kangfang Biotech and Xiansheng Pharmaceutical.
Entering the second quarter, the bank suggests focusing on the performance of A-share and US pharmaceutical companies' annual/quarterly reports, as well as data readings from important academic conferences; as sector investment sentiment stabilizes, stock prices are expected to continue to recover.